COVID-19 Antibody Seroconversion in Cancer Patients: Impact of Therapy Cessation-A Single-Center Study.
Lina SouanHikmat Abdel-RazeqSura NashwanSara Al BadrKamal Al-RabiMaher A SughayerPublished in: Vaccines (2023)
COVID-19 vaccines can still induce a humoral immune response in patients undergoing cancer-targeted therapy. The strength of this study is the long-term monitoring of antibody levels after vaccination in cancer patients on active therapy using two different immunoassays. Further multicenter studies with a larger number of patients are required to validate these findings.
Keyphrases
- immune response
- coronavirus disease
- sars cov
- patients undergoing
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- prognostic factors
- papillary thyroid
- peritoneal dialysis
- dendritic cells
- squamous cell carcinoma
- stem cells
- clinical trial
- toll like receptor
- inflammatory response
- young adults
- bone marrow
- mesenchymal stem cells
- childhood cancer
- lymph node metastasis